Foley & Lardner LLP partner Diane Hazel is quoted in the Reuters article, “FTC’s Amazon antitrust lawsuit faces high bar in US court – experts,” commenting on the U.S. Federal Trade Commission (FTC) and 17 state attorney generals’ recently filed lawsuit against Amazon.com, Inc. alleging that the online retail and technology company is a monopolist engaged in anticompetitive behavior.
Hazel explained that as part of the case, Amazon will have a chance to assert pro-competitive justifications for its alleged conduct, noting that the company would need to show its reasons are “legitimate” to count the FTC’s claims.
Hazel’s comments also appeared in Business of Fashion, Investing.com, U.S. News & World Report, and Yahoo! Finance.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”